In patients who resist immune checkpoint blockades, CD8+ T cells localize peritumorally, whereas they accumulate in the tumor mass in patients who respond to immune checkpoint blockade, suggesting that strategies aimed at promoting T-cell infiltration into the tumor mass are indispensable for the induction of therapeutic immunity [16,17]. The gene discussed is CD8A; the disease is neoplasm.